Skip to content

HGH (Somatropin)

Human Growth Hormone (HGH), also known as somatropin or somatotropin, is a 191 amino acid single-chain polypeptide hormone naturally produced by the anterior pituitary gland.

Also known as: Human Growth Hormone, 191aa Recombinant Growth Hormone, Somatropin

Typical Dose 0.15-0.3 mg/day (0.5-1 IU)
Storage Refrigerate reconstituted; store lyophilized powder away from light
How Often Once daily

Overview

Human Growth Hormone (HGH), also known as somatropin or somatotropin, is a 191 amino acid single-chain polypeptide hormone naturally produced by the anterior pituitary gland. Recombinant HGH (rhGH/somatropin) is bioidentical to endogenous growth hormone and is FDA-approved for growth hormone deficiency in children and adults, as well as several other conditions. The '191aa' designation refers to its complete 191 amino acid structure, distinguishing it from older 192aa formulations. HGH regulates growth, metabolism, body composition, and numerous physiological processes through direct actions and via stimulating IGF-1 production.

Key Benefits

  • Growth Hormone Deficiency
  • HIV-Associated Wasting
  • Fat Mass Reduction

Improved body composition (increased lean mass, decreased fat mass), enhanced bone mineral density, improved lipid profile, increased exercise capacity, better quality of life and mood, skin and hair improvements, enhanced recovery and healing

Mechanism of Action

HGH binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis stimulation, and metabolic regulation. Indirect effects occur via IGF-1 stimulation in liver and peripheral tissues, promoting growth, cell proliferation, and anabolism. Half-life: ~3 hours subcutaneously; peak levels 3-5 hours post-injection.

Research Protocols Injectable

GoalDoseFrequencyRoute
Medical GHD Replacement (Starting)0.15-0.3 mg/day (0.5-1 IU)Once dailySubcutaneous
Medical GHD Replacement (Maintenance)0.4-0.8 mg/day (1.2-2.4 IU)Once dailySubcutaneous
Anti-Aging / Wellness (Conservative)1-2 IU/day (0.33-0.67 mg)Once dailySubcutaneous
Body Recomposition (Moderate)2-4 IU/day (0.67-1.33 mg)Once or twice dailySubcutaneous
Performance (Higher - More Risk)4-8 IU/day (1.33-2.67 mg)Split twice dailySubcutaneous
Fasted Morning Protocol2-4 IUMorning on empty stomachSubcutaneous

Research protocols from published literature — not dosing recommendations.

Peptide Interactions

  • Insulin — Complex Interaction: HGH decreases insulin sensitivity and can cause insulin resistance. Diabetics may need increased insulin doses. Monitor blood glucose closely when combining
  • IGF-1 / IGF-1 LR3 — Synergistic but Caution: HGH stimulates endogenous IGF-1 production. Adding exogenous IGF-1 compounds effects but increases hypoglycemia and side effect risks
  • Thyroid Hormones (T3/T4) — Monitor Required: HGH increases T4 to T3 conversion and can unmask central hypothyroidism in 36-47% of patients. Monitor thyroid function; may require T4 supplementation
  • CJC-1295 — Synergistic: GHRH analog that stimulates natural GH release. Can be used with HGH for enhanced effects, though may be redundant if using adequate HGH doses
  • Ipamorelin — Synergistic: Ghrelin mimetic that stimulates GH release via different pathway. Combination may enhance overall GH/IGF-1 axis but increases complexity
  • GHRP-6 / GHRP-2 — Synergistic: Growth hormone releasing peptides work synergistically with HGH. Can enhance natural pulsatile release alongside exogenous administration
  • Cortisol / Hydrocortisone — Important Interaction: HGH can unmask cortisol deficiency in hypopituitary patients. Cortisol replacement should precede HGH therapy in patients with multiple deficiencies
  • Testosterone — Synergistic: Commonly combined in hormone replacement protocols. Both support anabolism, body composition, and well-being. Monitor estrogen conversion
  • Metformin — Monitor Combination: Metformin may be used to manage HGH-induced insulin resistance. Some evidence suggests metformin may reduce IGF-1 levels - monitor response
  • Semaglutide / Tirzepatide — Complementary: GLP-1 agonists may help manage HGH-induced insulin resistance while supporting fat loss goals. Increasingly combined in body composition protocols

Peptide Instructions Injectable

Supplies:

  • HGH lyophilized powder vial (typically 10 IU / 3.33 mg or 36 IU / 12 mg)
  • Bacteriostatic water for injection (BAC water)
  • Insulin syringes (29-31 gauge, 0.5 or 1 mL)
  • Alcohol prep pads
  • Sterile work surface
  • Refrigerator for storage (2-8°C)

How to Reconstitute Injectable

  1. 1Remove HGH vial from refrigerator and allow to reach room temperature (15-20 minutes)
  2. 2Clean the rubber stopper of both HGH vial and BAC water with alcohol swab
  3. 3Determine reconstitution volume - common: 1 mL BAC water per 10 IU vial (each 0.1 mL = 1 IU)
  4. 4Draw bacteriostatic water into syringe slowly, removing all air bubbles
  5. 5Insert needle into HGH vial at angle, aiming stream at vial wall - NOT directly on powder
  6. 6Inject BAC water slowly down the inside wall of the vial - drop by drop
  7. 7Remove needle and gently swirl vial in circular motion - NEVER SHAKE
  8. 8Allow to sit if any cloudiness, then swirl again until completely clear
  9. 9Solution should be crystal clear - discard if cloudy or contains particles
  10. 10Label vial with reconstitution date and concentration
  11. 11Store in refrigerator at 2-8°C, use within 14-28 days depending on product

What to Expect Injectable

Week 1-2: Improved sleep quality, increased energy, possible water retention and joint stiffness. Week 2-4: Enhanced recovery from exercise, skin beginning to improve, possible numbness/tingling in hands (carpal tunnel symptoms). Month 1-2: Noticeable fat loss beginning (especially abdominal), improved skin elasticity and texture. Month 2-3: Continued fat loss, lean mass improvements, hair/nail growth, reduced recovery time. Month 3-6: Significant body composition changes, improved bone density markers, sustained energy and well-being. Long-term: Maintained benefits with ongoing use; effects diminish over weeks-months after discontinuation. Note: Side effects (water retention, joint pain, carpal tunnel) often peak in first 4-8 weeks then improve.

Side Effects & Safety

FDA-approved only for specific medical conditions - off-label use carries legal and health risks. Start with low dose and increase gradually to minimize side effects (fluid retention, joint pain). Monitor blood glucose - HGH causes insulin resistance and can unmask or worsen diabetes. Monitor thyroid function - can unmask hypothyroidism; may require T4 supplementation. Contraindicated with active cancer - GH may accelerate tumor growth. Contraindicated in acute critical illness - increased mortality shown in ICU patients. Do not use for growth promotion in children with closed epiphyses. Carpal tunnel syndrome common - usually resolves with dose reduction or time. Long-term high-dose use associated with acromegaly-like side effects (enlarged features, organ growth). Not recommended during pregnancy or breastfeeding.

FDA-approved only for specific medical conditions - off-label use carries legal and health risks. Start with low dose and increase gradually to minimize side effects (fluid retention, joint pain). Monitor blood glucose - HGH causes insulin resistance and can unmask or worsen diabetes. Monitor thyroid function - can unmask hypothyroidism; may require T4 supplementation. Contraindicated with active cancer - GH may accelerate tumor growth. Contraindicated in acute critical illness - increased mortality shown in ICU patients. Do not use for growth promotion in children with closed epiphyses. Carpal tunnel syndrome common - usually resolves with dose reduction or time. Long-term high-dose use associated with acromegaly-like side effects (enlarged features, organ growth). Not recommended during pregnancy or breastfeeding.

Community Insights

HGH (Somatropin) should be stored at Lyophilized: refrigerate 2-8°C; Reconstituted: refrigerate, use within 14-28 days; Never freeze.

Molecular Information

Molecular Weight 22,124 Da (22 kDa)
Length 191
Type Single-chain polypeptide with two disulfide bridges
Sequence 191 amino acid single-chain protein with 4 cysteine residues forming 2 intrachain disulfide bonds. Identical to endogenous pituitary-derived hGH

References

  1. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients Johannsson G, Bidlingmaier M, Biller BMK, et al. · J Clin Endocrinol Metab 2022
  2. KIMS Long-Term Safety Study · 2022
  3. Effects on Morbidity - Systematic Review · 2014
  4. Adult Growth Hormone Deficiency - Benefits, Side Effects, and Risks of Growth Hormone Replacement Reed ML, Merriam GR, Kargi AY · Front Endocrinol (Lausanne) 2013
  5. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline Molitch ME, Clemmons DR, Malozowski S, et al. · J Clin Endocrinol Metab 2011
  6. The interaction between growth hormone and the thyroid axis in hypopituitary patients Behan LA, Monson JP, Agha A · Clin Endocrinol (Oxf) 2011
  7. Adult GHD Clinical Syndrome Characterization · 2011
  8. GH-Thyroid Hormone Interaction Study · 2011
  9. Effects of Growth Hormone on Glucose and Fat Metabolism in Human Subjects Jørgensen JO, Møller L, Krag M, et al. · Endocrinol Metab Clin North Am 2007
  10. Long-term efficacy and safety of somatropin for adult growth hormone deficiency Götherström G, Bengtsson BÅ, Bosaeus I, et al. · Clin Endocrinol (Oxf) 2005
  11. Long-term Efficacy and Safety in Adult GHD · 2005
  12. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials Maison P, Griffin S, Nicoue-Beglah M, et al. · J Clin Endocrinol Metab 2004
  13. GENOTROPIN Clinical Trials Program (1990s-2000s) · 1990

Research reference only. Not medical advice.